Imsapepimut is under clinical development by IO Biotech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imsapepimut’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imsapepimut overview
Imsapepimut is under development for the treatment of metastatic non-small cell lung cancer. It is a peptide vaccine containing a 21-mer IDO-derived peptide. The vaccine candidate is administered through intravenous and subcutaneous routes. It is developed based on T-win technology.
It was also under development for the treatment of malignant/metastatic melanoma.
IO Biotech overview
IO Biotech is a clinical-stage biopharmaceutical company that develops disruptive immune-modulating anti-cancer drugs. The company is investigating IO102-IO103, novel immune-modulating vaccines for the indications of melanoma and solid tumors. It also offers IO112 and IO170 product candidates for solid tumors. IO Biotech candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. It also utilizes T-win technology platform to discover, design and validate new immune-modulating vaccine candidates. The company operates in the US, Denmark and the UK. IO Biotech is headquartered in Copenhagen, Denmark.
For a complete picture of Imsapepimut’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
